Literature DB >> 23623439

Giant cell tumors of the tendon sheaths in the hand: review of 96 patients with an average follow-up of 12 years.

R Lancigu1, F Rabarin, J Jeudy, Y Saint Cast, B Cesari, P A Fouque, G Raimbeau.   

Abstract

INTRODUCTION: Giant cell tumors (GCT) of the hand are relatively common and have a good prognosis, but the risk of recurrence is high. The goal of this study was to evaluate the long-term clinical results of a consecutive series of patients and to determine the risk factors for recurrence.
MATERIAL AND METHODS: This was a retrospective study of 96 patients (57 women, 39 men) operated between February 1982 and October 2005 for GCT of the tendon sheaths in the hand. The average age at the time of the procedure was 47.7±14.5 years (range 13-75). All the patients were reviewed by an independent surgeon. The following were recorded: clinical result (QuickDASH, satisfaction), recurrence, histological appearance of tumor, location of tumor, excision margins and extension into the neighboring anatomical structures (tendon, joint). The tumor was located in the index finger in 29 cases, middle finger in 23 cases, thumb in 21 cases, ring finger in 11 cases, little finger in 11 cases, hypothenar area in two cases and thenar area in one case. In all cases, the lesion was isolated. The swelling was palmar in 27 cases, dorsal in 20 cases and medial or lateral in 59 cases. The most common joint location was the DIP joint (35% of cases). The swollen area was sensitive in 12 cases. The time from the appearance of the tumor to physician consultation ranged between 1 month and 7 years. Before the surgery, standard X-rays were taken in all patients; ultrasonography was also performed in eight patients and MRI in one patient. The tumor had an average diameter of 15.8±2.6mm (range 5-30). Histological analysis revealed a multilobed lesion with multinucleated giant cells, with or without encapsulation.
RESULTS: The average follow-up at the time of review was 12.1±3.8 years (range 5-29). There were eight recurrences in seven patients (8.3%). The average time to recurrence was 2.75±2 years (range 1-6.5). In every case of recurrence, there had been intra-articular tumor development and/or tendon destruction (P<0.01). There was one functional complication: one DIP joint fusion secondary to one of the recurrences. The average QuickDASH was 2.3/100 (range 0-31).
CONCLUSION: Giant cell tumors of the synovial sheaths in the hand are benign lesions where recurrence is the primary risk. The recurrence typically occurred within 36 months of the excision. Intra-articular tumor development, marginal resection and tendon involvement seem to contribute to recurrence. There was no correlation found between the histological type of tumor (encapsulated or not) and recurrence. LEVEL OF PROOF: IV.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23623439     DOI: 10.1016/j.otsr.2013.03.008

Source DB:  PubMed          Journal:  Orthop Traumatol Surg Res        ISSN: 1877-0568            Impact factor:   2.256


  4 in total

1.  Giant cell tumour of tendon sheath mimicking nodal osteoarthritis.

Authors:  Bhavana Pottabatula; Maryam Sattari
Journal:  BMJ Case Rep       Date:  2020-02-19

2.  Recurrent Tenosynovial Giant Cell Tumor (TGCT) in Thumb Treated by Excision and Adjuvant 3DCRT Radiation.

Authors:  J Terrence Jose Jerome; Loganathan Rajesh Sofia; Natesan Santhi
Journal:  Indian J Orthop       Date:  2022-06-13       Impact factor: 1.033

3.  Incidence and anatomical distribution of hand tumours: a Singapore study.

Authors:  Zhi Hao Tang; Vaikunthan Rajaratnam; Vijayadwaja Desai
Journal:  Singapore Med J       Date:  2016-08-29       Impact factor: 1.858

4.  Retrospective Study of the Results of Surgical Treatment of 31 Giant Cell Tumors of the Tendon Sheath in the Hand.

Authors:  José Antonio Galbiatti; Gabriel Rodrigues Dos Santos Milhomens; Luís Felipe Haber Figueiredo E Silva; Diego Dos Santos Santiago; José Cassimiro da Silva Neto; Sérgio de Oliveira Bruno Belluci
Journal:  Rev Bras Ortop (Sao Paulo)       Date:  2019-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.